NCT00699140已完成3 期
Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 8
- 主要终点
- Responder Patients
研究概览
简要总结
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.
详细描述
To determine if IGIV3I Grifols 10% is a consistently effective treatment in patients diagnosed with immune thrombocytopenic purpura with respect to:
- Increase of platelet count ≥ 50x10^9/L (primary objective).
- Time taken for the platelet count to reach ≥ 50x10^9/L.
- The length of time the platelet count remains ≥ 50x10^9/L.
- The maximum platelet level.
- Regression of bleeding episodes during the first 10 or 14 days.
To determine if IGIV3I Grifols 10% is safe with respect to:
Nature, severity and frequency of adverse reactions during and after infusions by percentage of subjects and percentage of infusions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 82 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be aged between 18 and 82 at the time of written consent.
- •Have confirmed diagnosis of chronic ITP and fulfil all the following criteria:
- •irrelevant history except for the symptoms of bleeding,
- •pattern of bleedings associated with platelet disorders,
- •physical examination irrelevant for the ITP, except for the signs of bleeding,
- •isolated thrombocytopenia in the blood count; apart from thrombocytopenia, the blood count is normal for the patient's age, or if abnormal, readily explained,
- •peripheral blood smear consistent with ITP: thrombocytopenia with platelets of normal size or slightly larger than normal, with absence of platelet clumps and giant platelets; normal red blood cell and white blood cell morphology,
- •confirmed diagnosis of immune thrombocytopenic purpura or, when any abnormal finding is present, additional diagnostic evaluation excludes other causes of thrombocytopenia.
- •Previous known diagnosis of ITP for at least 3 months.
- •To show a platelet count platelet count ≤ 20x10^9/L at the moment of the first infusion with the study product.
- •Have read the patient information and consent sheet, agreed to participate in the trial, and signed the consent sheet.
- •Be expected to receive treatment over 5 days and follow-up for 3 months.
- •For women of childbearing age, use adequate contraceptive method such as oral contraceptives, intrauterine device or tubal ligation during one-month period after the first infusion in the study.
排除标准
- •Have immune thrombocytopenia secondary to other pathologies or drug mediated thrombocytopenia.
- •Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
- •Present important active bleeding due to other reasons apart from the ITP.
- •Exhibit an identifiable alternative cause of their thrombocytopenia, such as splenomegaly, family thrombocytopenia, bacteraemia, sepsis or active infection requiring or not therapy.
- •Are presenting renal dysfunction.
- •Have non-controlled arterial hypertension.
- •Have documented liver cirrhosis or any hepatic disorder with alanine aminotransferase (ALT) levels 2.5 times or more than the normal upper limit or bilirubin greater than 2 mg/dL.
- •Are presenting a cardiac disease including a history of coronary artery disease, angina pectoris or congestive heart failure.
- •Present known infection due to HIV or hepatitis C virus (HCV).
- •Have been previously treated with IVIG or anti-D immunoglobulin being unresponsive.
- •Have a history of serious adverse reactions or non-serious but frequent adverse reactions to intravenous immune globulin (IVIG) preparations or other products derived from blood.
- •Have known allergies to any IGIV3I Grifols components, such as D-sorbitol.
- •Are simultaneously participating in other clinical studies or have received an investigational drug in the 3 months prior to the start of the study.
- •Have been involved in the present study and being treated with the formulation at 5% (IGIV3I Grifols 5%).
- •Have conditions that might affect patient compliance.
- •Are unable to provide a storage serum sample just before the first dose of IGIV3I Grifols.
- •Are pregnant or nursing an infant child or unwilling to practice adequate birth control in 1-month period after the first infusion in the study.
结局指标
主要结局
Responder Patients
时间窗: At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).
The primary efficacy endpoint was the proportion of patients who reached a platelet count ≥ 50x10\^9/L.
次要结局
- Length of Time Platelet Count Remains ≥ 50x10^9/L (≥ Days)(At any time during the study period (up to 3 months [90 days]))
- Maximum Platelet Level Reached During the Follow-up Period(During the follow-up period (time points: Days 6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1]))
- Time to Reach Platelet Count ≥ 50x10^9/L (≤ Days)(At any time during the study period (time points: Days 1-6, 10, 14, 21, 30, 60, 90 post-first infusion day [Day 1]))
- Regression of Hemorrhages.(First 10 to14 days since the first infusion day (Day 1))
- Frequency of Adverse Reactions During and After Infusions by Percentage of Patients(At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up))
- Frequency of Adverse Reactions During and After Infusions by Percentage of Infusions(At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up))
- Changes in Vital Signs and Clinically Relevant Changes in Laboratory Parameters After the Infusions, Including Renal Function (Creatinine Levels)(At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up))
- Viral Safety Through the Investigation of Patients Virology Status (Hepatitis A Virus [HA(At any time during the study period (from patient's signature of the informed consent form until 3 months of follow-up))
研究者
研究点 (8)
Loading locations...
相似试验
尚未招募
不适用
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsInhalational AnthraxNCT03569553Emergent BioSolutions100
尚未招募
不适用
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxAnthraxNCT03569514Emergent BioSolutions10
已完成
不适用
Study of CIDP Patients During IVIG TreatmentPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT00305266University of Aarhus11
撤回
不适用
Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive TractPostoperative ComplicationsPeritonitisNCT00511212Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group60
已完成
3 期
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)Primary Immune Deficiency Disorders (PIDD)NCT00538915ADMA Biologics, Inc.63